TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06018272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment (MBT)
Description: Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bona-Fide Treatment in Germany (BFT)
Description: Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (\>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
Study: NCT06518681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoliaValve (Aortic)
Description: Aortic Valve Replacement
Study: NCT05304065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAFETY-A within usual ED Care
Description: SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts
Description: COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
Study: NCT06499025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
Description: After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome mitoxantrone
Description: Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion
Study: NCT05667285

Intervention type: DEVICE
Intervention: BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System
Description: During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm.
Study: NCT06519773

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified periosteal inhibition
Description: After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant provided by Auto Fit Dental Implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A bone lamina and provided by GRANNTIE 1 mm thickness will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Modified periosteal inhibition
Description: After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant provided by Auto Fit Dental Implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A bone lamina and provided by GRANNTIE 1 mm thickness will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone.
Study: NCT04564976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support image
Description: An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
Study: NCT04994379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA tDCS
Description: One session with stimulation intensity of 1 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.5 mA tDCS
Description: One session with stimulation intensity of 1.5 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: One session of sham stimulation.
Study: NCT05024630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal artery cryoablation
Description: Renal denervation were achieved by cryoablation of renal artery with cryoballoon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulmonary vein cryoablation
Description: Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein cryoablation
Description: Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal arteriography
Description: Renal artery was examined by renal arteriography
Study: NCT04877795

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
Study: NCT04871165

Intervention type: DIAGNOSTIC_TEST
Intervention: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests
Description: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests
Description: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)
Description: Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)
Description: Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
Description: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
Description: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
Study: NCT06388681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography
Description: The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
Study: NCT06412484

Intervention type: BEHAVIORAL
Intervention: Pain Free Session
Description: On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.

Intervention type: BEHAVIORAL
Intervention: Pain Free Session
Description: On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.

Intervention type: BEHAVIORAL
Intervention: Low Back Pain Session (= clinically relevant pain)
Description: On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.

Intervention type: BEHAVIORAL
Intervention: Experimental Pain Session (= clinically irrelevant pain)
Description: On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
Study: NCT05290051

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optical Genome Mapping (Bionano®)
Description: Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Longread sequencing (Nanopore®)
Description: Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
Study: NCT05118724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
Study: NCT05059834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness resources
Description: a free mindfulness resource online for patients with general anxiety disorder

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
Study: NCT06065501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE intervention
Description: The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Nurses provide routine education and consultation
Study: NCT05802992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
Study: NCT06146023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic anastomosis (Symani surgical system and RoboticScope)
Description: Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anastomosis
Description: Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
Study: NCT06352411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for injection
Study: NCT04802564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular hand therapy
Description: edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular hand therapy
Description: edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
Study: NCT04626583

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic MSC
Description: Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic MSC
Description: Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic MSC
Description: Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
Study: NCT05805709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Physician/Advance Practice Provider
Description: The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigator
Description: The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist
Description: The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
Study: NCT05512247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Description: 10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
Study: NCT05538273

Intervention type: OTHER
Intervention: Early removal of urinary catheter postoperatively
Description: removal of urinary catheter less than 24 hours after surgery

Intervention type: OTHER
Intervention: Early removal of urinary catheter postoperatively
Description: removal of urinary catheter less than 24 hours after surgery

Intervention type: OTHER
Intervention: Early removal of urinary catheter postoperatively
Description: removal of urinary catheter less than 24 hours after surgery

Intervention type: OTHER
Intervention: Early removal of urinary catheter postoperatively
Description: removal of urinary catheter less than 24 hours after surgery

Intervention type: OTHER
Intervention: Late removal of urinary catheter postoperatively
Description: removal of urinary catheter greater than 24 hours after surgery

Intervention type: OTHER
Intervention: Late removal of urinary catheter postoperatively
Description: removal of urinary catheter greater than 24 hours after surgery

Intervention type: OTHER
Intervention: Late removal of urinary catheter postoperatively
Description: removal of urinary catheter greater than 24 hours after surgery

Intervention type: OTHER
Intervention: Late removal of urinary catheter postoperatively
Description: removal of urinary catheter greater than 24 hours after surgery
Study: NCT05226026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiteCAPP HELPS
Description: 4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered Withdrawal
Description: Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Tapered Withdrawal
Description: Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
Study: NCT05650320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406 Ointment
Description: Twice-daily administration for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406 Ointment
Description: Twice-daily administration for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0% OPA-15406 vehicle
Description: Twice-daily administration for 4 weeks.